Colistin is an antibiotic used to treat Gram-negative bacterial infections, particularly those caused by multidrug-resistant bacteria. The broth microdilution (BMD) reference method is the recommended protocol for detecting colistin susceptibility; however, it is laborious and expensive and cannot be performed in all laboratories. To evaluate the colistin susceptibility in , and using an alternative method, which has been referred to as the drop test. A 16 µg ml colistin solution was deposited on a Mueller-Hinton agar plate previously swabbed with the strain and incubated overnight, and the presence or absence of an inhibition zone was observed. The categorical agreement (CA) of the drop test with respect to BMD was 100 % when 190 Enterobacterales (19 and 171 . ) were used, and no major errors (MEs) or very major errors (VMEs) were detected. The CA of the drop test with respect to the BMD was 99.2 % for 119 . isolates, while no ME was detected and only 1 VME (6.7%) was observed. The drop test is an alternative method for antimicrobial susceptibility testing of colistin against and . It is an adequate method for detecting resistant strains of , but susceptible isolates should be confirmed using BMD. The drop test is a simpler alternative to the BMD that does not require additional equipment and allows for the testing of numerous isolates in a short period of time.

Download full-text PDF

Source
http://dx.doi.org/10.1099/jmm.0.001628DOI Listing

Publication Analysis

Top Keywords

drop test
24
colistin susceptibility
12
alternative method
8
test respect
8
respect bmd
8
major errors
8
test
6
colistin
6
method
5
bmd
5

Similar Publications

Background: Network neuropsychology is an emergent field dedicated to analyzing cognitive functions as interconnected systems. Although previous studies have explored cognitive network reorganization across the Alzheimer's disease (AD) continuum using comprehensive neuropsychological batteries, these approaches often overlook the potential of single screening tests used in routine clinical practice. This study innovatively applies graphical models to data from isolated neurocognitive tests, specifically the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), to construct cognitive networks.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

University of Kentucky, Lexington, KY, USA.

Background: Amylin is a systemic hormone that is co-secreted with insulin from pancreatic β-cells. Amylin co-aggregates with brain parenchymal and vascular β-amyloid in persons with Alzheimer's dementia. The present pilot study sought to assess the safety and side effects during and after the treatment period of passive amylin immunotherapy in the APP/PS1 mouse model of Alzheimer's disease.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Burke Neurological Institute, Weill Cornell Medicine, White Plains, NY, USA.

Background: Benfotiamine, a prodrug of thiamine, raises blood levels by 50-100 times to achieve pharmacologic effects. It provides a novel therapeutic direction addressing a well-characterized brain tissue thiamine deficiency and related changes in glucose metabolism in AD. BenfoTeam is a seamless phase 2A-2B "proof of concept" (POC), double-blind, placebo-controlled RCT investigating tolerability, safety, and efficacy of benfotiamine, as a first-in-class small molecule treatment for early AD.

View Article and Find Full Text PDF

Background: Antibiotic resistance (AR) is a growing concern as a result of the widespread and excessive use of antibiotics. Because of this, China's health authorities have implemented a number of antibiotic control measures, including a requirement that the intensity of antibiotic usage stay within 40.00 DDDs.

View Article and Find Full Text PDF

Evaluation of the efficacy, safety, and satisfaction rate of topical latanoprost in patients with hypopigmented burn scars treated with fractional CO2 laser: a double-blind randomized controlled clinical trial.

Lasers Med Sci

January 2025

Department of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences (IUMS), Niayesh Street, Sattar Khan Avenue, Rasool Akram Hospital, Tehran, Iran.

Burn scars present psychological and social challenges for patients, classified into atrophic and hypertrophic types. Treatments like corticosteroid injections, laser therapy, and platelet-rich plasma (PRP) injections are commonly recommended for hypertrophic scars, while regenerative medicine and fractional CO2 lasers are linked to some degree of improvement for atrophic scars. Hypopigmented and depigmented burn scars pose ongoing challenges for healthcare providers and patients, with therapies such as intense pulsed light and fractional CO2 laser showing variable effects in treating these conditions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!